Aim Immunotech IncAIM
ASignal's systematic analysis rates AIM as Bearish.
Reflects the latest available analysis · analyzed Aug 22, 2026
The case on AIM
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Current price near upper end of Bollinger Bands suggests potential breakout
- Positive MACD histogram indicates strengthening momentum
- Cash position ($9.96M) exceeds total debt ($3.92M), providing runway
- Current ratio of 2.11x indicates short-term liquidity strength
- Negative operating cash flow (-$14.37M) and free cash flow (-$14.06M)
- Extremely negative operating margin (-13511.54%) and return on equity (-2382.30%)
- Revenue growth of only 4.00% YoY in a high-growth sector
- High EV/Revenue (19.19x) and Price-to-Sales (82.80x) relative to minimal growth
- Forward P/E of -0.70x indicates negative earnings expectations
- No Reddit mentions, suggesting lack of retail investor interest
See the full verdict on AIM
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes AIM
Most investors never get a second opinion, let alone several. ASignal runs AIM past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.